Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injectable medications used primarily for the management of type 2 diabetes mellitus and, in some formulations, for weight management in adults with obesity or overweight with comorbidities
same drug, different label) If you have moderate obesity (BMI 30 to 35): Semaglutide (Ozempic for diabetes, Wegovy for obesity) or liraglutide (Victoza for diabetes, Saxenda for obesity) If you want the simplest regimen: Once-weekly semaglutide or tirzepatide Goal: Minimize injection frequency Once weekly: Semaglutide, tirzepatide, dulaglutide, efpeglenatide, retatrutide Every two weeks (pipeline): Ecnoglutide (pending approval) Oral (no injections): Semaglutide (Rybelsus) or orforglipron (Orfoglip) Goal: Minimize gastrointestinal side effects Lower nausea profile: Tirzepatide (dual agonist
These results follow similar findings from the companys ATTAIN-1 trial released earlier this month, which tested the drug on people who were overweight or obese without type 2 diabetes (in general, people without diabetes tend to lose more weight from GLP-1 therapy than those with diabetes)
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS
